Home » Elahere (Mirvetuximab Soravtansine)
Buy Elahere in India — Price & Availability
Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (FRα)-directed antibody-drug conjugate given as an intravenous infusion to treat FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is not commercially marketed in India, but can be legally imported on a valid prescription through the Named Patient Program. Indian Pharma Network sources it from licensed US/EU manufacturers and qualified pharmaceutical supply channels with full cold-chain handling.
Looking to buy Elahere in India? Elahere (mirvetuximab soravtansine-gynx) is a prescription cancer medicine that is not yet commercially marketed in India, but can be legally accessed through the Named Patient Program (NPP).
- Brand name: Elahere®
Generic (API): Mirvetuximab soravtansine-gynx - Strength & form: 100 mg / 20 mL (5 mg/mL) solution in a single-dose vial
- Route: Intravenous (IV) infusion
- Drug class: Folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC)
- Manufacturer: AbbVie Inc. (originally developed by ImmunoGen, Inc.)
- Availability in India: Via Named Patient import (not locally marketed)
Prescription: Required — oncologist supervised
Medically reviewed for accuracy by the Indian Pharma Network (IPN) clinical content team · Last updated: 30 June 2026 · For informational use; not a substitute for advice from your oncologist.
What is Elahere used for?
Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (FRα)-directed antibody-drug conjugate. It links a chimeric IgG1 antibody that targets the FRα protein on cancer cells to DM4, a microtubule inhibitor payload, via a cleavable linker. After the antibody binds FRα, the conjugate is taken into the cell and releases DM4, delivering the cytotoxic drug more directly to the tumour.
It is approved for adults with:
- FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Patient eligibility is confirmed by an approved test for FRα expression. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.
Recommended dosage:
The recommended dose of Elahere is 6 mg/kg of adjusted ideal body weight (AIBW), given as an intravenous infusion once every 3 weeks (a 21-day cycle), continued until disease progression or unacceptable toxicity.
- Elahere is given only as an IV infusion — never as an IV push or bolus.
- Pre-medications are given before each infusion to reduce infusion reactions and nausea, and prophylactic eye care (artificial tears and topical steroid eye drops) is used to lower the risk of eye problems.
- The first infusion is typically given at a slower rate with observation; later infusions may be given faster if well tolerated.
- The dose may be interrupted, reduced, or stopped to manage side effects.
The treating oncologist always determines dosing, the number of cycles, and any modifications.
Boxed warning: Elahere carries a boxed warning for ocular (eye) toxicity, including visual impairment, keratopathy (corneal changes), dry eye, photophobia (light sensitivity), eye pain, and uveitis. Eye examinations (including visual acuity and slit-lamp exams) are done before starting treatment, every other cycle for the first 8 cycles, and as clinically needed. Prophylactic eye drops are used, and treatment may be adjusted based on eye findings.
- Ocular toxicity: report any new or worsening vision changes promptly; do not use contact lenses unless advised by the treating team.
- Pneumonitis (lung inflammation): can be serious; report new or worsening cough, shortness of breath, or fever, as treatment may need to be interrupted or stopped.
- Peripheral neuropathy: numbness, tingling, pain, or weakness in the hands or feet should be reported; the dose may be modified.
- Effects on driving/machinery: blurred vision or neuropathy may affect the ability to drive or operate machinery.
- Embryo-fetal toxicity: Elahere can harm an unborn baby; effective contraception is advised during treatment and for 7 months after the last dose, and breastfeeding is not recommended during and for 1 month after treatment.
Common side effects:
Frequently reported effects include blurred vision and other eye changes (keratopathy, dry eye), fatigue, nausea, diarrhoea, abdominal pain, peripheral neuropathy, musculoskeletal pain, constipation, vomiting, decreased appetite, and changes in certain blood and liver tests (such as increased AST/ALT and decreased blood counts). This is not a complete list — refer to the full prescribing information and your oncologist.
Patients in India can legally access Elahere through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:
- Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
- Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
- Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
- Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
- Cold-chain import & delivery — Elahere is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.
Documents required to import Elahere:
- A valid prescription from a qualified oncologist
- The patient’s diagnostic reports, including FRα (folate receptor alpha) test results
- Government-issued patient ID proof
- An import permit, where applicable
Because Elahere is not sold on the open market in India, there is no fixed MRP. The Elahere cost in India depends on a few factors at the time of import:
- The number of 100 mg vials required per cycle, which is based on the patient’s adjusted ideal body weight and the every-3-week dosing schedule.
- The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
- Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.
Get a transparent quote: We provide a written quotation covering Elahere cost, logistics, and delivery timeline once a valid prescription is shared. Request your Elahere quote →
Elahere is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.
Indian Pharma Network sources Elahere from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Elahere vials require cold-chain handling: stored upright in a refrigerator at 2 °C–8 °C in the original carton, protected from light, and never frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.
Detail | Information |
Storage | Refrigerate upright at 2 °C to 8 °C in the original carton; protect from light; do not freeze or shake |
Sourcing regions | USA, Europe, Canada, China, Japan, Australia |
Delivery | To the patient’s address or treating hospital, under cold-chain logistics |
Order confirmation | After verification of a valid prescription and import permit (where applicable) |
Elahere can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.
How can I buy Elahere in India?
Elahere is not commercially marketed in India, but it can be legally accessed through the Named Patient Program. With a valid oncologist’s prescription, diagnostic reports (including FRα test results), and a government-issued patient ID, Indian Pharma Network facilitates compliant import in the patient’s name.
What is the price of Elahere in India?
Elahere in India is not sold on the open market, so the cost depends on sourcing, the number of vials required, logistics, and applicable duties at the time of import. A transparent, patient-specific quote is provided once the prescription is verified.
What is Elahere used for?
It treats adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Who manufactures Elahere?
Elahere is manufactured by AbbVie. It was originally developed by ImmunoGen, which AbbVie acquired. It is a first-in-class folate receptor alpha-directed antibody-drug conjugate.
What is the dosage form and strength of Elahere?
Elahere is supplied as a 100 mg / 20 mL (5 mg/mL) solution in a single-dose vial, given as an intravenous infusion after dilution by a healthcare professional. The recommended dose is 6 mg/kg of adjusted ideal body weight every 3 weeks.
How is Elahere stored and delivered?
Elahere vials are stored upright, refrigerated at 2 °C to 8 °C, in the original carton, protected from light and never frozen or shaken, and shipped under validated cold-chain conditions to the patient or treating hospital.
Request Elahere price & availability:
Speak with our patient support team for the exact price, a transparent quote, and guidance on the Named Patient import process. We respond within 24 hours on business days.
- Call: +91-96548 60915
- WhatsApp: +91-98104 69557
- Toll-free: 1800-1200-365
- Email: info@indianpharmanetwork.in
References & sources
- Elahere (mirvetuximab soravtansine-gynx) US Prescribing Information, AbbVie Inc.
- US Food & Drug Administration — Elahere approval history (accelerated approval 14 November 2022; full approval 22 March 2024).
- European Medicines Agency — Elahere product information.
- Therapeutic Goods Administration (TGA) – Elahere
- National Cancer Institute – Elahere in Ovarian Cancer
- WebMed – Elahere for Ovarian, Fallopian Tube, Peritoneal Cancer
Content reviewed by the Indian Pharma Network clinical content team. Indications, dosing, and safety information are summarised from the manufacturer’s prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
Elahere® (mirvetuximab soravtansine-gynx injection) is a prescription anticancer medicine and should only be used under the supervision of a qualified healthcare professional. Indian Pharma Network is a pharmaceutical trading entity that facilitates access to medicines through legally permissible channels, such as Named Patient import, strictly against valid prescriptions. All trademarks and brand names remain the property of their respective owners (Elahere® is a registered trademark of the AbbVie group of companies) and are used for identification only. This page is for informational purposes and does not constitute medical advice. Product availability, import requirements, and pricing vary by country-specific regulations.